Smith & Nephew faces long and painful activist fix
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Aimee Donnellan
LONDON, July 4 (Reuters Breakingviews) -Smith & Nephew SN.L should prepare for a long and painful activist treatment. On Thursday, Swedish investor Cevian Capital announced it had taken a 5% stake in the $11 billion UK-listed maker of hip joints and wound care kit. Its medicine is likely to involve stripping out costs. If that fails, more radical remedies like a breakup may be necessary.
Smith & Nephew has many ingredients activists look for in a target. Its share price has fallen 42% over the past five years, whereas the FTSE 100 Index .FTSE is up by 10%. Endless management churn can’t have helped: during that same period the group has had three CEOs and three chief financial officers. Its boss, Deepak Nath, has introduced a 12-point plan to increase the company’s performance.
Investors, however, are not convinced. Including debt, Smith & Nephew is valued at $14 billion, just 13 times its expected operating profit in 2025, according to LSEG data, a steep discount to its five-year average of 18 times. Cevian has not yet disclosed its demands, but the activist could push Nath to take a bigger axe to Smith & Nephew’s bloated cost base, which resulted in an operating margin of just 17% last year. U.S.-listed rival Stryker SYK.N generated a 24% margin.
Assume Smith & Nephew can close half the profitability gap with Stryker, and its EBIT margin would reach 21%. Apply that to the $6.7 billion of revenue the London-listed firm is expected to deliver in 2027, and operating profit could total $1.4 billion that year. Next, assume a leaner, more profitable Smith & Nephew is valued at 17 times forward EBIT, again closing half the gap with Stryker’s multiple, and its enterprise value could exceed $24 billion in two years. That’s nearly 70% higher than its current worth.
If Nath fails, deeper surgery may be necessary. Last year the orthopaedic division that makes artificial hip and knee joints was the slowest growing of Smith & Nephew’s business units. Selling that to a rival, like Stryker, could free up cash to invest in the other two units, wound care and sports injuries. Alternatively, switching its primary listing to the United States may attract more investors, and a higher valuation. But a recovery is likely to take time. As activist campaigns go, Smith & Nephew will be more than a quick fix.
Follow @aimeedonnellan on X
CONTEXT NEWS
Activist investor Cevian said on July 4 it has taken a 5% stake in Smith & Nephew, the London-listed manufacturer of medical devices.
Shares in Smith & Nephew were up 6.3% at 1,047 pence by 0734 GMT.
Graphic: Smith & Nephew’s valuation is lagging rivals https://reut.rs/3VOCqIp
Editing by Neil Unmack and Oliver Taslic
Ativos relacionados
Últimas notícias
Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.
Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.
Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.
